Yijiang Shi

2.8k total citations
35 papers, 2.2k citations indexed

About

Yijiang Shi is a scholar working on Molecular Biology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Yijiang Shi has authored 35 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 22 papers in Hematology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Yijiang Shi's work include Multiple Myeloma Research and Treatments (22 papers), PI3K/AKT/mTOR signaling in cancer (22 papers) and Cancer Mechanisms and Therapy (6 papers). Yijiang Shi is often cited by papers focused on Multiple Myeloma Research and Treatments (22 papers), PI3K/AKT/mTOR signaling in cancer (22 papers) and Cancer Mechanisms and Therapy (6 papers). Yijiang Shi collaborates with scholars based in United States, Mexico and Canada. Yijiang Shi's co-authors include Alan Lichtenstein, Joseph Gera, Patrick Frost, Jung-Hsin Hsu, Bao Hoang, Huajun Yan, Liping Hu, Angelica Benavides, Myrna Fisher and Chris Tran and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Cancer Research.

In The Last Decade

Yijiang Shi

35 papers receiving 2.2k citations

Peers

Countries citing papers authored by Yijiang Shi

Since Specialization

Citations

This map shows the geographic impact of Yijiang Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yijiang Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yijiang Shi more than expected).

Fields of papers citing papers by Yijiang Shi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yijiang Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yijiang Shi. The network helps show where Yijiang Shi may publish in the future.

Co-authorship network of co-authors of Yijiang Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Yijiang Shi. A scholar is included among the top collaborators of Yijiang Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yijiang Shi. Yijiang Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on Cancer Therapies including Immunotherapy 2023 ·Biomolecules ·Yijiang Shi, Daniel Sanghoon Shin	12
2	Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma 2022 ·Molecular Cancer Therapeutics ·Yijiang Shi, Fumou Sun, Yan Cheng, Brent Holmes, Binod Dhakal, Joseph Gera, Siegfried Janz, Alan Lichtenstein	4
3	Turnover of the mTOR inhibitor, DEPTOR, and downstream AKT phosphorylation in multiple myeloma cells, is dependent on ERK1-mediated phosphorylation 2022 ·Journal of Biological Chemistry ·Mario I. Vega, Yu Chen, Yijiang Shi, Joseph Gera, Alan Lichtenstein	5
4	A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity 2019 ·Molecular Cancer Therapeutics ·Mario I. Vega, Yijiang Shi, Patrick Frost, Sara Huerta‐Yépez, (unknown), Rogélio Hernández‐Pando, Jihye Lee, Michael E. Jung, Joseph Gera, Alan Lichtenstein	8
5	Structure-activity relationship study of small molecule inhibitors of the DEPTOR-mTOR interaction 2017 ·Bioorganic & Medicinal Chemistry Letters ·Jihye Lee, Yijiang Shi, Mario I. Vega, Yonghui Yang, Joseph Gera, Michael E. Jung, Alan Lichtenstein	10
6	SGK Kinase Activity in Multiple Myeloma Cells Protects against ER Stress Apoptosis via a SEK-Dependent Mechanism 2016 ·Molecular Cancer Research ·Bao Hoang, Yijiang Shi, Patrick Frost, (unknown), Carolyne Bardeleben, Alan Lichtenstein	10
7	Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells 2016 ·Cancer Research ·Yijiang Shi, Tracy R. Daniels‐Wells, Patrick Frost, (unknown), Richard S. Finn, Carolyne Bardeleben, Manuel L. Penichet, Michael E. Jung, Joseph Gera, Alan Lichtenstein	19
8	Metabolomics Identifies Pyrimidine Starvation as the Mechanism of 5-Aminoimidazole-4-Carboxamide-1-β-Riboside-Induced Apoptosis in Multiple Myeloma Cells 2013 ·Molecular Cancer Therapeutics ·Carolyne Bardeleben, Sanjai Sharma, Joseph R. Reeve, Sara Bassilian, Patrick Frost, Bao Hoang, Yijiang Shi, Alan Lichtenstein	29
9	Mammalian Target of Rapamycin Inhibitors Induce Tumor Cell ApoptosisIn VivoPrimarily by Inhibiting VEGF Expression and Angiogenesis 2013 ·Journal of Oncology ·Patrick Frost, (unknown), (unknown), Bao Hoang, Yijiang Shi, Joseph Gera, Alan Lichtenstein	31
10	MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells 2012 ·Oncogene ·Yijiang Shi, Patrick Frost, Bao Hoang, Yonghui Yang, Rikiro Fukunaga, Joseph Gera, Alan Lichtenstein	22
11	The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/ Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance 2012 ·Journal of Biological Chemistry ·Bao Hoang, Angelica Benavides, Yijiang Shi, Yonghui Yang, Patrick Frost, Joseph Gera, Alan Lichtenstein	63
12	IL-6-induced Enhancement of c-Myc Translation in Multiple Myeloma Cells 2010 ·Journal of Biological Chemistry ·Yijiang Shi, Patrick Frost, Bao Hoang, Angelica Benavides, Joseph Gera, Alan Lichtenstein	35
13	Effect of autophagy on multiple myeloma cell viability 2009 ·Molecular Cancer Therapeutics ·Bao Hoang, Angelica Benavides, Yijiang Shi, Patrick Frost, Alan Lichtenstein	124
14	Cyclin D1 and c-myc Internal Ribosome Entry Site (IRES)-dependent Translation Is Regulated by AKT Activity and Enhanced by Rapamycin through a p38 MAPK- and ERK-dependent Pathway 2005 ·Journal of Biological Chemistry ·Yijiang Shi, Anushree Sharma, Hong Wu, Alan Lichtenstein, Joseph Gera	129
15	Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade 2005 ·Molecular Cancer Therapeutics ·Yijiang Shi, Huajun Yan, Patrick Frost, Joseph Gera, Alan Lichtenstein	308
16	Interleukin-6 activates phosphoinositol-3′ kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways 2004 ·Oncogene ·Jung-Hsin Hsu, Yijiang Shi, Patrick Frost, Huajun Yan, Bao Hoang, Sanjai Sharma, Joseph Gera, Alan Lichtenstein	49
17	AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression 2004 ·Journal of Biological Chemistry ·Joseph Gera, Ingo K. Mellinghoff, Yijiang Shi, Matthew B. Rettig, Chris Tran, Jung-Hsin Hsu, Charles L. Sawyers, Alan Lichtenstein	284
18	Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses 2002 ·Oncogene ·Jung-Hsin Hsu, Yijiang Shi, Liping Hu, Myrna Fisher, Thomas Franke, Alan Lichtenstein	69
19	Signal Pathways Involved in Activation of p70S6K and Phosphorylation of 4E-BP1 following Exposure of Multiple Myeloma Tumor Cells to Interleukin-6 2002 ·Journal of Biological Chemistry ·Yijiang Shi, Jung-Hsin Hsu, Liping Hu, Joseph Gera, Alan Lichtenstein	96
20	Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. 2002 ·PubMed ·Yijiang Shi, Joseph Gera, Liping Hu, Jung-Hsin Hsu, Robert Bookstein, Weiqun Li, Alan Lichtenstein	198

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact